• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents

Article

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with.

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with. “Now, until recently that whole idea of risks versus benefits was really about the benefits of the medicine versus the risks of tolerability issues,” said Dr Kantor. “So not of major safety issues.” Self-injectables may be a burden to some, they have a long-term safety profile. Though convenient, newer oral medications have more safety concerns and risks. It is imperative that physicians work with their individual patients to manage risks when using new agents.

Related Videos
Annie Antar, MD, PhD, Johns Hopkins Medicine
Leigh Maria Ramos-Platt, MD
Michelle Hessen, OD
Annie Antar, MD, PhD, Johns Hopkins Medicine
Barry Byrne, MD
Giulio Cossu, MD
Dr Toon Van Gorp
AAD 2025 Recap
Brittany Craiglow, MD, FAAD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.